PHARMACY

Diplomat closes TNH Specialty Pharmacy acquisition

BY David Salazar
FLINT, Mich. — Diplomat Pharmacy on Thursday announced that it had completed its acquisition of Valley Campus Pharmacy, which does business as TNH Advanced Specialty Pharmacy providing individualized patient care in Van Nuys, Calif. 
 
“The combined resources of both companies opens new sales synergies and makes our services stronger in the evolving specialty pharmacy market.” Diplomat CEO and president Phil Hagerman said. “TNH's established physician referral presence in California and Texas strengthens Diplomat's footprint in key geographic markets. Further, the recent purchase of a licensed Texas facility to enable brick-and-mortar presence will allow us to open the door to service the state's 3.7 million Medicaid patients. As we integrate TNH into our family of companies, we will be leveraging their expertise, while remaining focused on providing care one patient at a time.”
 
Diplomat has paid TNH — which brought in $400 million in revenue in 2015 — $65 million in cash and $10 million in Diplomat common stock. The company expects the acquisition to be accretive to earnings in 2016. 
 
“Diplomat is a family-grown business guided by the philosophy, ‘Take good care of the patients and the rest falls into place,’” TNH CEO Avo Minasyan said. “We share that same philosophy, and are committed to maintaining the highest standards of customer care in the industry. TNH was founded based on the need to improve industry standards through technology for advanced specialty pharmacy services. Together, we will continue the dedication to high-touch management programs to enhance the entire care experience.”
 
keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

Mylan launches generics of Vidaza injection, Rythmol capsules

BY David Salazar
PITTSBURGH — Mylan on Thursday launched two new generic products. The company rolled out its generic of Celgene’s Vidaza (azacitidine, 100 mg/vial) injection and its generic of GSK’s Rhythmol (propafenone HCl) extended-release capsules. 
 
Vidaza is indicated to treat the five French-American-British subtypes of myelodysplastic syndrome, a blood cell disorder that can be the result of cancer treatments or can progress to leukemia. It had sales of approximately $236.3 million in the U.S. for the 12 months ended March 31, according to IMS Health. 
 
Rythmol is indicated to prolong the time to recurrence of symptomatic atrial fibrillation (AF) in patients with episodic AF who don’t have structural heart disease. The drug had U.S. sales of about $100.5 million for the 12 months ended March 31, according to IMS Health. Mylan’s generic will be available in 225-, 325- and 425-mg dosage strengths. 
 
keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

VoicePort expands automated solutions that support patient care

BY David Salazar

Though VoicePort’s best-known offering is its PharmaPhonetics platform — which provides multichannel, automated and personalized communications to help pharmacies engage with patients — the Rochester, N.Y.-based company has expanded its offerings as the pharmacist’s role has expanded beyond filling prescriptions to helping patients lead healthy lives.

(Click here to view the full Category Review.)

“Our company is focused on leveraging automation to support core pharmacy patient-care solutions and profit objectives to deliver added quality and improved Star ratings,” VoicePort VP business development Alphonse Sasso told Drug Store News recently.

The company last October inked a deal with Costco’s Canadian pharmacies to provide some of its solutions to the chain. The company’s suite of solutions currently includes SYNCHRO-SCRIPT for medication synchronization and a platform for integrated immunization services, among others. The company’s offerings, according to Sasso, can help pharmacies with data integration, analytics and operational expertise.

VoicePort’s medication synchronization tool, SYNCHRO-SCRIPT, in particular, is aimed at automating a complicated process to help drive and pave the way for more pharmacist interventions that can improve patient health.

“Our medication synchronization solution works to help the pharmacy team align the patient’s meds and keep them aligned to a convenient once-a-month regimen,” Sasso said. “Having this automated approach in place to recommend an anchor med, offer short-fill calculations and get patients enrolled in the program offers pharmacies added time to meet with the patient to support other clinical interventions like MTM, immunizations, patient education and other important opportunities available in our platform.”

When it comes to immunization services, VoicePort’s solution is integrated with Scientific Technologies Corp.’s immunization intelligence platform to help pharmacies identify which vaccinations a patient is missing.

“Via the direct integration with STC, our platform has the capability to query the appropriate State Immunization Information Service, provide patient-specific immunization forecasting and automatically comply with state-specific reporting requirements,” Sasso said. “By leveraging our state-of-the-art, cloud-based communication technology, we can notify each eligible patient of their vaccination needs and capture their responses for action by the pharmacy team.

For the company, better outcomes begin with adherence through close collaboration with its pharmacy partners.

“Keeping patients adherent to their meds prescribed by their healthcare professional is key to allowing them to live happy, healthy and productive lives,” Sasso said. “Our No. 1 priority at VoicePort is to ensure that we are surpassing all of our cli-ent’s expectations, and we pride ourselves on the valuable and trusting relationships we have built with each VoicePort client.”

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?